Recently, we characterized mouse monoclonal antibodies that allow the specific and sensitive detection of human histamine N-methyltransferase (HNMT). To understand differences in binding characteristics and recognition of enzyme variants we mapped the antibody binding sites.
Methods
Fragments of human HNMT were expressed as glutathione S-transferase fusion proteins that were used for testing antibody binding on immunoblots. Combined information from species cross-reactivity, sequence comparison, protein structure, and binding site prediction software were used to localize the epitope recognized by each antibody.
Results
All eight monoclonal HNMT antibodies bound to linear epitopes in the C-terminal domain of the 292 amino acid protein. Of the five antibodies cross-reacting with HNMT from other species, one bound region L182–T223, three region M224–E261, and one region L262–A292. All three antibodies recognising only human HNMT bound the C-terminal region L262–A292 that contains residues present only in the human protein.
Conclusions
Our HNMT monoclonal antibodies bind in three different regions of the protein and those binding the same putative epitope exhibit similar binding characteristics and species cross-reactivity. Antibodies binding non-overlapping epitopes will facilitate analyses of all clinically relevant variants described for HNMT.
Hinweise
Responsible Editor: John Di Battista.
Abkürzungen
DAO
Diamine oxidase
GST
Glutathione S-transferase
HDC
Histidine decarboxylase
HNMT
Histamine N-methyltransferase
SNP
Single nucleotide polymorphism
Introduction
Histamine binds and activates four different G-protein-coupled receptors and thereby mediates many biological processes including inflammation, gastric acid secretion, neuromodulation, and regulation of immune function [1, 2]. Histamine exhibits pharmacological activity at very low concentrations, and therefore, its synthesis, transport, storage, release and degradation have to be tightly regulated to avoid undesirable reactions. Histamine synthesis is catalyzed by the enzyme histidine decarboxylase (HDC, EC 4.1.1.22) through decarboxylation of the amino acid l-histidine [3, 4]. In mammals, histamine can be inactivated either by oxidative deamination of the primary amino group, catalyzed by diamine oxidase (DAO, EC 1.4.3.22), or by methylation of the imidazole ring, catalyzed by histamine N-methyltransferase (HNMT, EC 2.1.1.8) [4‐6].
Human HNMT is a small monomeric protein of 33 kDa consisting of a single polypeptide chain of 292 amino acid residues and catalyzes the transfer of a methyl group from S-adenosyl-l-methionine (SAM) to the secondary amino group of the imidazole ring of histamine forming Nτ-methylhistamine [6]. The human protein is encoded by a single gene designated HNMT that has six exons and has been mapped to chromosome 2q22.1 [7]. HNMT has a two-domain structure with the larger N-terminal domain being a classic methyltransferase fold with an SAM binding motif [8]. HNMT exhibits high substrate specificity for histamine and is inhibited by its reaction products, as well as by the SH-group reagents p-chloromercuribenzoate and N-ethylmaleimide and by the antimalarial drugs quinacrine and amodiaquine [6]. HNMT is a cytosolic protein that is responsible for the inactivation of intracellular histamine, which is either synthesized in the cell or taken up from the extracellular space after binding to one of its receptors present on the cell surface or by plasma membrane transporters [2, 4].
Anzeige
To characterize the human histamine-inactivating enzymes, we recently produced and characterized a series of mouse monoclonal antibodies specific for DAO and HNMT, respectively [9, 10]. These antibodies turned out to be invaluable tools for the study of the expression and cellular localization of the enzymes. The eight monoclonal antibodies binding human HNMT exhibited considerable differences in their binding characteristics and species cross-reactivity [10]. Additionally, we wanted to know if our antibodies recognize and can be used to detect the enzyme variants that have been described resulting from single nucleotide polymorphisms (SNPs) of the HNMT gene and that might be relevant for diseases associated with impaired histamine inactivation [11, 12]. Therefore, we tested antibody binding to various fragments of the HNMT protein expressed in vitro and combined these results with data from sequence comparison, species cross-reactivity, structural information, and binding site prediction tools to map the epitopes recognized by the different HNMT antibodies.
Materials and methods
Preparation and expression of recombinant human HNMT protein fragments
Full-length human HNMT cDNA [13, 14] was amplified by PCR with specific primers from total human kidney cDNA and cloned in frame into the BamHI site of the bacterial expression vector pGEX-2T (GE Healthcare, Vienna, Austria) to obtain plasmid pGEX-huHMT01 [10]. A series of C-terminal deletions of HNMT was produced by double-digestion of pGEX-huHMT01 with restriction endonucleases EcoRI100, XhoI322, NdeI419, KpnI491, NcoI668, or BglII792 (superscripts indicate position of recognition sequence relative to A of translational start codon) that cut once on the cDNA plus SmaI that cuts the vector immediately downstream of the cloning site, creating blunt ends by incubation for 15 min at 37 °C with 1 U Klenow Fragment and 100 µM dNTPs, and religating the respective larger fragments with T4 DNA ligase, resulting in plasmids pGEX-huHMT02-07. Fragments of the C-terminal region of HNMT were produced by digesting the 882 bp BamHI fragment of full-length HNMT cDNA with KpnI or AluI + NcoI, creating blunt ends with Klenow Fragment, and ligating the gel-purified fragments KpnI491–BamHI880, AluI543–NcoI668, NcoI668–AluI783, and AluI783–BamHI880 in frame into the SmaI site of pGEX-5X-1 or pGEX-5X-2, respectively (GE Healthcare, Vienna, Austria), resulting in plasmids pGEX-huHMT08-11. All cloning enzymes were obtained from Thermo Scientific (Vienna, Austria). The clones were checked by DNA sequence analyses and their inserts and the resulting HNMT protein fragments are illustrated in Fig. 1a and detailed in Table 1.
Fig. 1
HNMT expression constructs. a Recombinant plasmids expressing GST-HNMT fusion proteins obtained by cloning different human HNMT cDNA fragments into the bacterial expression vectors pGEX-2T or pGEX-5X-1/-2, respectively. b 10% silver-stained SDS polyacrylamide gel and immunoblot with an anti-GST antibody of lysates prepared from bacteria harbouring plasmids pGEX-huHMT01-11 indicated on top of each lane. Migration positions of full-length fusion proteins are indicated by arrows and their expected sizes are listed in Table 1. The sizes of molecular weight markers (M) are given on the left in kDa
Table 1
Expression plasmids for huHNMT fragments
Plasmid
Vector
cDNA fragment
Peptide
FuP (kDa)
pGEX-huHMT01
pGEX-2T
BamHI1–BamHI880
M1–A292
56.1
pGEX-huHMT02
pGEX-2T
BamHI1–BglII792
M1–K264
53.0
pGEX-huHMT03
pGEX-2T
BamHI1–NcoI668
M1–T223
48.5
pGEX-huHMT04
pGEX-2T
BamHI1–KpnI491
M1–T164
42.0
pGEX-huHMT05
pGEX-2T
BamHI1–NdeI419
M1–H140
39.4
pGEX-huHMT06
pGEX-2T
BamHI1–XhoI322
M1–N107
35.8
pGEX-huHMT07
pGEX-2T
BamHI1–EcoRI100
M1–Q33
27.6
pGEX-huHMT08
pGEX-5X-1
KpnI491–BamHI880
N165–A292
38.1
pGEX-huHMT09
pGEX-5X-2
AluI543–NcoI668
L182–T223
28.6
pGEX-huHMT10
pGEX-5X-1
NcoI668–AluI783
M224–E261
29.2
pGEX-huHMT11
pGEX-5X-2
AluI783–BamHI880
L262–A292
27.4
Human HNMT cDNA fragments obtained with different restriction endonucleases were cloned in frame into the expression vectors pGEX-2T or pGEX-5X-1/-2 to produce different size GST-HNMT fusion proteins (FuP). Superscripts indicate position of restriction site on cDNA sequence and amino acid position, respectively
×
Each recombinant plasmid was transformed into the protease-deficient strain E. coli BL21 to produce glutathione S-transferase (GST) fusion proteins according to the manufacturer’s instructions (GE Healthcare, Vienna, Austria). Briefly, recombinant bacteria were grown at 37 °C with slight agitation (100 rpm) in 10 ml YTA (16 g/l tryptone, 10 g/l yeast extract, 5 g/l NaCl, 100 mg/l ampicillin, pH 7.0) to an OD600nm of 0.5 and fusion protein expression was induced for 4 h by addition of 0.1 mM isopropyl-β-d-thiogalactopyranoside (IPTG, Roche, Vienna, Austria). Bacteria were harvested by centrifugation for 5 min at 4000×g, 4 °C, washed with cold deionized water, and lysed in SDS sample buffer by incubation for 10 min at 95 °C. Cell lysates were cleared by centrifugation for 5 min at 10,000×g and stored at −20 °C until use. Fusion protein expression was analyzed by SDS polyacrylamide gel electrophoresis [15] and Western blotting [16] using the GST-specific monoclonal antibody HYB374-01, which showed considerable expression for all constructs (Fig. 1b).
Testing of the binding of HNMT specific monoclonal antibodies
Monoclonal antibodies HYB372-04/-05/-06/-07/-08/-09 and HYB373-02/-03 specific for human HNMT [10] were tested for binding to different HNMT fragments using filter strips of cell lysates containing the expressed GST fusion proteins. Cleared cell lysates prepared in SDS sample buffer containing approximately 100 µg of protein were separated on 12.5% SDS polyacrylamide gels [15] and blotted onto polyvinylidene fluoride (PVDF) membranes [16]. After washing in TBST (50 mM Tris·HCl, pH 7.5, 150 mM NaCl, 0.1% Tween 20) and blocking non-specific binding sites by incubation for 60 min at 4 °C in TBSTM (TBST containing 2% non-fat dry milk) the membranes were cut into 20 vertical filter strips each containing circa 5 µg of protein. Each filter strip was incubated for 16 h at 4 °C with suitable dilutions of the monoclonal antibodies in TBSTM, washed 4 × 5 min with TBST, incubated for 60 min at 4 °C with horseradish peroxidase-conjugated anti-mouse immunoglobulins (Dako, Glostrup, Denmark) diluted 1:1500 in TBSTM, washed for 4 × 5 min with TBST, incubated for 5 min with ECL reagent (GE Healthcare, Vienna, Austria), and exposed to Cronex 5 film (Agfa, Mortsel, Belgium).
Anzeige
Immunoprecipitation experiments were carried out to test if the antibodies also bind the native HNMT protein. Total lysates were prepared from human and porcine kidney and liver, respectively, by homogenization of ca. 50 mg tissue in 1 ml lysis buffer (20 mM bis·Tris·HCl, pH 7.0, 5 mM dithiothreitol) containing Complete Protease Inhibitor Cocktail (Roche, Vienna, Austria) for 5 min at 30 Hz using a TissueLyser II homogenizer (Qiagen, Hilden, Germany). Lysates were cleared by centrifugation for 10 min at 20,000×g, 4 °C and the supernatant containing the total soluble protein was stored at −20 °C until used. Lysates containing comparable HNMT activity were incubated with slight agitation in a total volume of 100 µl with different concentrations of the monoclonal HNMT antibodies for 16 h at 4 °C, followed by incubation with Protein A-Sepharose (GE Healthcare, Vienna, Austria) for 1 h at 4 °C. Immunoprecipitates were separated by centrifugation for 1 min at 6700×g, 4 °C, washed three times with TBST, and solubilized in SDS sample buffer. The presence of HNMT was analyzed in the precipitate and in the supernatant by immunoblotting with HYB372-07 and HNMT activity was determined in the supernatant by methylation of histamine with S-adenosyl-l-[methyl-14C]methionine (GE Healthcare, Vienna, Austria) as described previously [17]. Precipitation with a non-specific monoclonal antibody served as control.
Mapping of binding sites using binding information, sequence comparison, and antibody cross-reactivity
HNMT polypeptide sequences were aligned using the NCBI constrained-based Multiple Alignment Tool (http://www.ncbi.nlm.nih.gov/tools/cobalt/cobalt.cgi?link_loc=BlastHomeLink) [18]. Antigenicity plots were produced with the BepiPred Linear Epitope Prediction Tool (tools.immuneepitope.org/bcell) [19]. For testing species cross-reactivity, filter strips prepared from cleared tissue lysates of human, porcine, rat, and mouse kidney were incubated with different HNMT antibodies and developed as described above. For detection of weak bands, ECL Prime reagent (GE Healthcare, Vienna, Austria) was substituted for ECL reagent. Structural views were created with the NCBI Cn3D 4.3.1 software [20] using HNMT structure 1JQD [8].
Results
Using human and porcine HNMT expressed in vitro as antigens, we recently produced a series of mouse monoclonal antibodies that bind to human HNMT and facilitate the specific and sensitive detection of the protein on immunoblots of human lysates and by immunohistochemical staining of human tissues [10]. Antibody clones HYB372-04/-05/-06/-07/-08/-09 resulted from immunization with human HNMT and clones HYB373-02/-03 resulted from immunization with porcine HNMT but cross-reacted with human HNMT [10]. To analyse where on the human HNMT protein these eight antibodies bind, a series of C-terminal deletions of the 292 amino acid HNMT protein was constructed by recombinant DNA technology and the resulting polypeptides were expressed as GST fusions in bacteria (Fig. 1a; Table 1). Bacterial lysates containing considerable amounts of the respective fusion proteins (Fig. 1b) were then separated by SDS polyacrylamide gel electrophoresis and blotted onto PVDF membranes to test the binding of the antibodies.
As expected and shown in Fig. 2a, all antibodies gave a strong signal with the GST-HNMT fusion protein containing full-length 292 amino acid human HNMT expressed by plasmid pGEX-huHMT01. Antibodies HYB372-04/-05/-06 and HYB373-02 did not bind any of the shorter fusion proteins indicating that their binding requires residues downstream of BglII792 or D265, respectively. Antibodies HYB372-08/-09 and HYB373-03 also bound the fusion protein produced by pGEX-huHMT02 but none of the shorter fragments, indicating that binding requires residues downstream of NcoI668 or M224, respectively. Antibody HYB372-07 also bound the fusion protein produced by pGEX-huHMT03 but none of the shorter fragments, indicating binding requires residues downstream of KpnI491 or N165, respectively.
Fig. 2
Antibody binding to HNMT fragments. Antibody binding was tested using filter strips of HNMT fragments with C-terminal deletions (a) or of HNMT fragments from the C-terminal region (b). Filter strips containing approximately 5 µg of cell lysate protein separated on a 12.5% SDS polyacrylamide gel were incubated with the mouse monoclonal antibodies HYB372-04/-05/-06/-07/-08/-09, HYB373-02/-03 (diluted 1:1000–1:20000 in TBSTM), and the anti-GST antibody HYB374-01 (1:1500), respectively. Filter strips were then incubated with horseradish peroxidase-conjugated anti-mouse immunoglobulins (1:1500 in TBSTM), followed by ECL substrate, and exposure to film for 0.25–10 min. Lane numbers 1–7 and 8–11 correspond to expression constructs pGEX-huHMT01-07 and pGEX-huHMT08-11, respectively, and binding is indicated by plus and minus signs below each lane. Exact positions of the bands on parallel lanes vary slightly because filter strips from different individual blots were used for this experiment. Besides the major band of the respective full-length fusion protein, a variable number of smaller bands are visible in most lanes due to production of partial products in the bacterial expression system
×
The fact that an antibody does not bind a fusion protein lacking a certain C-terminal fragment could either mean that the complete binding site is located in the missing region or that part of the missing region is necessary for forming a proper binding site or conformation with a region further upstream. Therefore, we next constructed clones expressing fragments of the C-terminal region of HNMT as GST fusions and tested these for antibody binding (Fig. 1; Table 1). As shown in Fig. 2b, all antibodies bound the GST fusion of the HNMT peptide N165–A292 expressed from plasmid pGEX-huHMT08 confirming that their binding sites are indeed located in that C-terminal region of the protein. When testing shorter non-overlapping fragments from this region, we found that HYB372-07 bound peptide L182–T223 expressed from pGEX-huHMT09, HYB372-08/-09 and HYB373-03 bound peptide M224–E261 expressed from pGEX-huHMT10, and HYB372-04/-05/-06 and HYB373-02 bound peptide L262–A292 expressed from pGEX-huHMT11 (Fig. 2b). Thus, the binding sites of all antibodies could be localized on specific small peptides in the C-terminal region of HNMT and appeared to be linear epitopes.
HYB372-07 produced strong HNMT specific bands on blots of human, pig, and rat kidney lysates of comparable HNMT enzymatic activity but hardly any signal with a mouse kidney lysate (Table 2). Therefore, this antibody should bind a peptide that is nearly identical in man, pig, and rat but different in mouse. In the HYB372-07 binding region L182–T223 only the C-terminal peptide K214–T223 meets this requirement with identical sequences in all species except for position 221 where a leucine in human, pig, and rat HNMT is replaced by a valine in mouse HNMT (Fig. 3a). Moreover, this peptide appears not to be completely exposed on the protein surface (Fig. 3b, c), which might explain the fact that HYB372-07 does not immunoprecipitate native human or porcine HNMT (Table 2).
Table 2
Properties of human HNMT specific monoclonal antibodies
Antibody
Isotype
huHNMT
piHNMT
raHNMT
moHNMT
IPhu
IPpi
BR
HYB372-07
IgG1κ
++
++
++
+/−
−
−
L182–T223
HYB372-08
IgG1κ
++
++
++
+
+
+
M224–E261
HYB372-09
IgG1κ
++
++
++
+
+
+
M224–E261
HYB373-03
IgG1κ
++
++
++
+
+
+
M224–E261
HYB372-04
IgG1κ
++
−
−
−
++
−
L262–A292
HYB372-05
IgG1κ
++
−
−
−
++
−
L262–A292
HYB372-06
IgG1κ
++
−
−
−
++
−
L262–A292
HYB373-02
IgG1κ
+
+
−
−
−
−
L262–A292
Species cross-reactivity was tested on blots of human (hu), pig (pi), rat (ra), and mouse (mo) kidney lysates that had comparable HNMT enzymatic activity. Immunoprecipitation of HNMT was tested with human (IPhu) and porcine (IPpi) kidney and liver lysates, respectively. The binding region (BR) specifies the peptide of human HNMT recognized on blots
++, strong; +, weak; −, no binding or immunoprecipitation
Fig. 3
Localization of antibody binding sites. a Alignment of human, pig, rat and mouse HNMT polypeptide sequences of the C-terminal domain L161–A292 with predicted linear epitopes indicated by asterisk on top. Residues identical in all four proteins are shaded black, residues identical in three proteins are shaded gray, and residues that have been shown to interact with histamine in human HNMT [8] are shaded red, respectively. Peptide fragments used for testing antibody binding are shown below the sequence with the antibodies binding to them. b Protein backbone model and c space filling model of human HNMT structure 1JQD [8] with the methyltransferase fold to the left and the antibody binding peptide residues L182–T223, M224–E261, and L262–A292 highlighted in red, green, and blue, respectively. Histamine (HIS) and S-adenosyl-l-homocysteine (SAH) bound to HNMT are visible as ball-and-stick models in b but are hidden by the polypeptide chain in c (color figure online)
×
HYB372-08/-09 and HYB372-02, which bound in region M224–E261, also produced strong HNMT bands on blots of human and pig kidney lysates, slightly weaker bands with a rat lysate, and very weak bands with a mouse lysate but partially immunoprecipitated native human and pig HNMT (Table 2). Thus, these antibodies should bind a peptide that is nearly identical in man and pig, slightly different in rat and significantly different in mouse. Only the C-terminal peptide T247–E261 of region M224–E261 contains variant sequences starting at N249 and including a notable change of N251A252 present in human and pig HNMT to IK in rat and SK in mouse HNMT. This peptide has been predicted as a likely epitope in human and pig HNMT [19] and is accessible on the surface of the HNMT protein in accordance with the immunoprecipitation results (Fig. 3a–c).
HYB372-04/-05/-06, which bound in region L262–A292, produced strong HNMT bands only on blots of human kidney lysates but did not react with HNMT from other species and exhibited strong immunoprecipitation of native human HNMT (Table 2). Therefore, these antibodies should bind a peptide on the surface of HNMT with distinct sequence differences in the human protein. The peptide L262–E276 predicted as a likely epitope [19] contains residues L262, G263, and A273 in human HNMT that are different in all other HNMT sequences (Fig. 3a) and forms a well-exposed loop on the surface of the protein (Fig. 3b, c). In contrast, HYB373-02 binding in region L262–A292 produced only weak HNMT bands on blots of human and pig kidney lysates, did not react with rat and mouse HNMT, and did not immunoprecipitate human or pig HNMT (Table 2). Accordingly, this antibody probably binds peptide G277–V289 that contains a conservative substitution of T284 in human HNMT to S284 in pig HNMT but a non-conservative substitution to N in rat and mouse HNMT (Fig. 3a) and is not accessible on the surface of the native protein (Fig. 3b, c).
Anzeige
Discussion
The binding sites of eight mouse monoclonal antibodies specific for human HNMT [10] were determined by antibody binding on blots of HNMT protein fragments expressed in vitro combined with information from species cross-reactivity, sequence comparison, protein structure, and binding site prediction software. With this approach binding of the antibodies could be mapped to relatively short linear peptide fragments in the C-terminal domain of HNMT including K214–T223 for HYB372-07, T247–E261 for HYB372-08/-09 and HYB373-03, L262–E276 for HYB372-04/-05/-06, and G277–V289 for HYB373-02. Although we did not map the exact epitopes using specific peptides and thus the actual binding sites might be slightly larger or smaller than designated above, the position information is adequate to state that different antibodies bind to separate, non-overlapping regions and to explain the different species cross-reactivity of the antibodies and the surface accessibility of each binding site.
These antibodies were obtained by immunization of mice with recombinant full-length human and porcine HNMT, respectively, that had full enzymatic activity, and therefore, probably was in their native conformation, and initial screening was done by ELISA using the native proteins as antigens [10]. Whereas all antibodies exhibited excellent binding to denatured HNMT on Western blots and in immunohistochemistry, only HYB372-04/-05/-06/-08/-09 and HYB373-03 were able to immunoprecipitate enzymatically active HNMT from human kidney and liver lysates, indicating that the epitopes recognized by these antibodies are accessible on the surface of the native protein (Table 2; Fig. 3b, c). In contrast, HYB372-07 and HYB373-02 did not immunoprecipitate native human HNMT, indicating a limited accessibility of their respective epitopes on the native protein. Interestingly, the putative binding regions of the antibodies immunoprecipitating HNMT were accurately predicted by the binding site prediction software [19] whereas those of the antibodies not immunoprecipitating HNMT were not (Fig. 3a; Table 2).
HYB372-04/-05/-06 bound only to human HNMT but not to pig, rat, and mouse HNMT and HYB373-02 bound only to human and pig HNMT but not to rat and mouse HNMT, which is probably a consequence of distinct sequence differences in the putative binding regions (Fig. 3a). So these antibodies will be useful only for analyses of the human and porcine HNMT proteins, respectively. On the other hand, HYB372-07/-08/-09 and HYB373-03 exhibited strong binding to human, pig, and rat HNMT and very weak binding to mouse HNMT (Table 2), which can be explained by the sequence conservation of the putative binding regions in different species and small but significant sequence differences in mice (Fig. 3a). As the respective HNMT sequences are conserved in many other species besides those tested here, these antibodies will also be useful for studies of the HNMT protein in other model organisms.
In conclusion, the eight HNMT monoclonal antibodies bound in three different regions of the protein and those binding the same putative epitope exhibited similar binding characteristics and species cross-reactivity. Having a collection of antibodies binding separate non-overlapping epitopes will facilitate the comprehensive analysis of native human HNMT but also of all HNMT variants resulting from altered HNMT gene sequences. Our binding studies with partial HNMT peptide fragments showed that the antibodies will bind to any HNMT variant that contains an unaltered binding sequence. The antibodies will be especially useful for the study of SNPs leading to amino acid substitutions associated with altered enzyme function that might be relevant for various human diseases such as the T105I substitution associated with reduced enzyme activity and stability [11] as well as the G60D and the L208P substitutions identified in patients with intellectual disability [12].
Anzeige
Acknowledgements
Open access funding provided by University of Innsbruck and Medical University of Innsbruck. This work was supported by Grant P14923 from the Austrian Science Fund and by COST Action BM0806.
Compliance with ethical standards
Conflict of interest
The authors declare that there is no conflict of interest regarding the publication of this paper.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Mit e.Med Dermatologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Dermatologie, den Premium-Inhalten der dermatologischen Fachzeitschriften, inklusive einer gedruckten dermatologischen Zeitschrift Ihrer Wahl.
Verzögertes Wiederanspringen der Darmfunktion ist ein Hauptfaktor dafür, wenn Patientinnen und Patienten nach einer Kolonresektion länger als geplant im Krankenhaus bleiben müssen. Ob man diesem Problem mit Lidocain vorbeugen kann, war Thema einer Studie.
Zum Thema Koronare Herzkrankheit gab es 2024 wichtige neue Studien. Beleuchtet wurden darin unter anderem der Stellenwert von Betablockern nach Herzinfarkt, neue Optionen für eine Lipidsenkung sowie die Therapie bei infarktbedingtem kardiogenem Schock.
Ergebnisse einer Phase-III-Studie sprechen dafür, dass die Behandlung mit CDK4/6-Inhibitoren bei fortgeschrittenem HR-positivem, HER2-negativem Brustkrebs auch auf die Zweitlinie verschoben werden könnte, ohne die onkologischen Ergebnisse zu kompromittieren.
Ob inhalative Kortikosteroide (ICS) COPD-Kranke außer vor akuten Exazerbationen auch vor kardiovaskulären Komplikationen schützen können, ist unklar. Eine bevölkerungsbasierte Studie aus England spricht nicht dafür.
In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln. Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.
